



**(301) 366-4960**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On September 13, 2014, the compensation committee (“Committee”) of Neuralstem, Inc. (the “Company”) ratified an increase in salary for Dr. Karl Johe, the Company’s Chief Scientific Officer. The Committee set Dr. Johe’s salary at \$750,000 effective January 1, 2014. No other provisions of Dr. Johe’s employment agreement were changed.

**Item 9.01**

**Financial Statement and Exhibits.**

**Exhibit Number Description**

10.01 Form of Employment Agreement Amendment of Dr. Karl Johe

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr

Chief Executive  
Officer

Dated: September 18, 2014



EXHIBITS

**Exhibit**

**Description**

**Number**

10.01 Form of Employment Agreement Amendment of Dr. Karl Johe